bispecific versus car t-cell therapy for myeloma and bridging therapy needs for car-t
Published 1 year ago • 440 plays • Length 8:14Download video MP4
Download video MP3
Similar videos
-
5:05
myeloma treatment selection: car-t versus bispecific t-cell engagers, bridging therapy options
-
4:01
what are the differences between car t-cell therapy and bispecific antibodies?
-
6:47
toxicity management: car-ts versus bispecific t-cell engagers
-
4:35
bispecific antibodies vs car t-cells for r/r multiple myeloma
-
4:34
what is the future for car-t in multiple myeloma?
-
3:47
what is car t-cell therapy?
-
0:45
bispecific car t-cell therapy: combining anti-cd19 and cd22 car t-cells
-
8:00
treatment selection for relapsed multiple myeloma: car-t versus bispecifics
-
7:55
real-world car-t outcomes, use of ide-cel, cilta-cel for myeloma
-
2:45
emerging treatments for myeloma: quadruplets, bispecific antibodies & car t-cells
-
4:12
is there an ideal space for allogeneic car-t products for myeloma?
-
4:27
the possibility of combining car-t therapy and bispecific antibodies in the treatment of nhl
-
3:06
car-t and bites – which targets belong in clinical practice?
-
0:39
car-t, bispecifics and mrd: how is treatment for multiple myeloma evolving?
-
1:46
car-t therapy vs bites in multiple myeloma: current outlooks & the importance of patient selection
-
1:14
the car t-cell strategy vs bispecific antibodies
-
3:41
bcma bispecific toxicities, access considerations
-
19:37
bispecific monoclonal antibodies and car t-cell therapy in multiple myeloma, omar nadeem, md
-
3:19
bispecific car t-cell therapy as treatment for hard to treat multiple myeloma